Tags : Orthofix

PharmaShots Weekly Snapshot (February 10-14, 2020)

1. Epizyme Reports the US FDA Acceptance of NDA for Tazverik (tazemetostat) to Treat Follicular Lymphoma Published: Feb 14, 2020 | Tags: Epizyme, Reports, US, FDA, Acceptance, NDA, Tazverik, tazemetostat, Follicular Lymphoma 2. Soligenix’s RiVax Receives the US FDA’s Fast Track Designation for the Prevention of Ricin Poisoning Published: Feb 13, 2020 | Tags: Soligenix, RiVax, Receives, […]Read More

Orthofix’s STIM onTrack 2.1 Mobile App Receives the US FDA’s

Shots: The STIM onTrack technology is designed to work with Orthofix’s bone growth therapy devices, aid patients in adhering to their prescription and to improve their clinical outcomes The news version of the mobile application captures the Patient Reported Outcome Measure (PROM) that enables patients to share their clinical responses in their home setting. The […]Read More